Compare Cytokinetics Inc (CYTK) vs T-Rex 2X Long MSTR Daily Target ETF (MSTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs T-Rex 2X Long MSTR Daily Target ETF — how do they compare? Cytokinetics Inc trades at $62.5 (market cap $8.62B), while T-Rex 2X Long MSTR Daily Target ETF trades at $40.11 (market cap $809.00M). The key difference: Cytokinetics Inc is far larger — about 10.7× T-Rex 2X Long MSTR Daily Target ETF's market cap, and Cytokinetics Inc is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and T-Rex 2X Long MSTR Daily Target ETF for 18 Days on average.
| CYTK | MSTU | |
|---|---|---|
Market Cap | $8.62B | $809.00M |
Volume | 2,594,626 | 4,577,465 |
Sector | Health | Leveraged / Inverse |
52-Week High | $87.26 | $451.00 |
52-Week Low | $54.76 | $14.60 |
Typical Hold Time | 19 Days | 18 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
MSTU trades at $39.54, showing minimal daily movement with a 0.23% gain. The technical outlook is bearish based on moving averages, while oscillators present a neutral stance. Recent corporate actions include a 10:1 reverse stock split and a $0.29 dividend scheduled for August 2026. News coverage highlights the ETF's leveraged nature and recent volatility concerns.
The outlook remains cautious due to the bearish technical signals and leveraged ETF structure, which amplifies volatility. Investment opportunities exist for tactical traders seeking short-term momentum, but risks include daily rebalancing effects and potential value erosion during sustained market moves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About T-Rex 2X Long MSTR Daily Target ETF
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →
